Physician profile
Manoharan W Eustace
NPI 1487614723
$4,386.42
in general payments reported to CMS, 2019-2025
40 companies · $693 in 2025
The $693 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $569 · 2020: $321 · 2021: $919 · 2022: $979 · 2023: $378 · 2024: $527 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,598.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $446.86 | 2021-2025 | |
| Glaxosmithkline, LLC. | $354.66 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $295.59 | 2019-2022 | |
| Lilly USA, LLC | $282.56 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $263.81 | 2021-2025 | |
| Novo Nordisk INC | $254.92 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $254.29 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $242.65 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $241.73 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $225.94 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $212.26 | 2022-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $138.39 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $128.55 | 2019-2021 | |
| Urovant Sciences INC | $107.11 | 2022 | |
| Allergan, INC. | $92.91 | 2019-2020 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fidia Pharma USA INC. | $92.30 | 2019-2022 | |
| Biogen, INC. | $71.81 | 2020-2022 | |
| Exact Sciences Corporation | $68.03 | 2023-2024 | Cologuard Collection Kit |
| Ucb, INC. | $60.18 | 2020-2021 | |
| Abbott Laboratories | $58.29 | 2022-2023 | Freestyle Libre 3 |
| Horizon Therapeutics Plc | $44.90 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $44.30 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $39.52 | 2022 | |
| Amgen INC. | $33.92 | 2021 | |
| Dexcom, INC. | $31.94 | 2021 | |
| Merck Sharp & Dohme LLC | $27.80 | 2021 | |
| Acadia Pharmaceuticals INC | $27.06 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.98 | 2024 | Jardiance |
| Pulmonx Corporation | $25.19 | 2021-2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Eisai INC. | $24.42 | 2021 | |
| Edwards Lifesciences Corporation | $23.81 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Sk Life Science, INC. | $23.18 | 2022 | |
| Boston Scientific Corporation | $21.77 | 2022 | |
| Hologic Sales and Service, LLC | $19.99 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $16.52 | 2024 | |
| Kyowa Kirin, INC. | $15.37 | 2020 | |
| Amarin Pharma, INC. | $13.61 | 2020 | |
| Avanir Pharmaceuticals, INC. | $12.76 | 2019 | |
| Alkermes, INC. | $11.50 | 2019 | |
| Clarus Therapeutics INC. | $10.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manoharan Eustace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.